Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$13.43 -0.5%	$13.89	$7.64 ▼ $17.75	$1.60B	1.76	2.26 million shs	2.23 million shs
BHVN Biohaven	$15.43 -1.1%	$18.21	$14.33 ▼ $55.70	$1.58B	0.95	1.27 million shs	1.36 million shs
IRON Disc Medicine	$53.71 +1.9%	$45.86	$30.82 ▼ $68.73	$1.86B	0.73	348,602 shs	705,215 shs
TNGX Tango Therapeutics	$4.69 -7.1%	$2.02	$1.03 ▼ $12.02	$508.37M	1.24	1.48 million shs	2.44 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	0.00%	-6.54%	-1.47%	-8.14%	+65.80%
BHVN Biohaven	0.00%	-9.21%	-2.43%	-47.25%	-54.32%
IRON Disc Medicine	0.00%	+7.38%	+14.06%	+5.27%	+38.25%
TNGX Tango Therapeutics	0.00%	+10.09%	+208.55%	+140.51%	-38.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	1.8835 of 5 stars	3.4	1.0	2.1	1.7	0.6
BHVN Biohaven	2.9909 of 5 stars	4.5	1.0	1.8	2.5	0.6
IRON Disc Medicine	2.1723 of 5 stars	3.5	2.0	2.2	2.5	0.0
TNGX Tango Therapeutics	2.1233 of 5 stars	3.5	1.0	4.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.83	Moderate Buy	$18.80	39.99% Upside
BHVN Biohaven	3.07	Buy	$59.46	285.46% Upside
IRON Disc Medicine	3.09	Buy	$96.70	80.04% Upside
TNGX Tango Therapeutics	3.00	Buy	$12.20	160.13% Upside

Current Analyst Ratings Breakdown

Latest TNGX, IRON, BHVN, and ARQT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	IRON Disc Medicine	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$89.00
5/23/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/19/2025	BHVN Biohaven	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$54.00 ➝ $21.00
5/13/2025	BHVN Biohaven	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	BHVN Biohaven	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$61.00 ➝ $54.00
5/12/2025	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $120.00
4/28/2025	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $57.00
4/24/2025	BHVN Biohaven	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/14/2025	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/9/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/3/2025	ARQT Arcutis Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$212.82M	7.52	N/A	N/A	$0.94 per share	14.29
BHVN Biohaven	N/A	N/A	N/A	N/A	$5.34 per share	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.17 per share	N/A
TNGX Tango Therapeutics	$40.99M	12.40	N/A	N/A	$2.48 per share	1.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$262.14M	-$1.04	N/A	N/A	N/A	-140.97%	-119.11%	-45.95%	8/13/2025 (Estimated)
BHVN Biohaven	-$408.17M	-$9.36	N/A	N/A	N/A	N/A	-225.12%	-158.89%	8/5/2025 (Estimated)
IRON Disc Medicine	-$76.43M	-$3.92	N/A	N/A	N/A	N/A	-25.24%	-23.96%	8/6/2025 (Estimated)
TNGX Tango Therapeutics	-$101.74M	-$1.22	N/A	N/A	N/A	-284.42%	-49.64%	-32.00%	8/6/2025 (Estimated)

Latest TNGX, IRON, BHVN, and ARQT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/12/2025	Q1 2025	TNGX Tango Therapeutics	-$0.34	-$0.36	-$0.02	-$0.36	$6.73 million	$5.39 million
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
5/6/2025	Q1 2025	ARQT Arcutis Biotherapeutics	-$0.21	-$0.20	+$0.01	-$0.20	$64.80 million	$65.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.67	2.46	2.38
BHVN Biohaven	N/A	2.89	2.89
IRON Disc Medicine	N/A	19.36	19.36
TNGX Tango Therapeutics	N/A	8.00	8.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
BHVN Biohaven	88.78%
IRON Disc Medicine	83.70%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
BHVN Biohaven	16.00%
IRON Disc Medicine	4.24%
TNGX Tango Therapeutics	6.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.20 million	105.93 million	Optionable
BHVN Biohaven	239	102.11 million	84.94 million	Optionable
IRON Disc Medicine	30	34.63 million	28.50 million	Not Optionable
TNGX Tango Therapeutics	90	108.39 million	100.65 million	Optionable

TNGX, IRON, BHVN, and ARQT Headlines

Recent News About These Companies

FY2025 EPS Estimate for Tango Therapeutics Lifted by Analyst

June 14 at 1:45 AM | americanbankingnews.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 7.4% - Here's What Happened

June 13 at 3:17 PM | marketbeat.com

Equities Analysts Offer Predictions for TNGX FY2026 Earnings

June 13 at 2:57 AM | americanbankingnews.com

Tango Therapeutics (NASDAQ:TNGX) Shares Gap Down - Time to Sell?

June 12 at 3:47 PM | marketbeat.com

B. Riley Expects Higher Earnings for Tango Therapeutics

June 12 at 8:24 AM | marketbeat.com

Brokers Offer Predictions for TNGX Q2 Earnings

June 12 at 1:19 AM | americanbankingnews.com

Cantor Fitzgerald Predicts TNGX FY2026 Earnings

June 11, 2025 | marketbeat.com

Q2 Earnings Forecast for TNGX Issued By B. Riley

June 11, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 11.8% - Should You Buy?

June 10, 2025 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Holdings Increased by Bank of America Corp DE

June 9, 2025 | marketbeat.com

Millennium Management LLC Invests $771,000 in Tango Therapeutics, Inc. (NASDAQ:TNGX)

June 7, 2025 | marketbeat.com

Tango Therapeutics: PRMT5 Data Readout Due In 2025 Is Critical

June 6, 2025 | seekingalpha.com

Analysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) Target Price at $12.20

June 6, 2025 | americanbankingnews.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Buy" by Analysts

June 3, 2025 | marketbeat.com

Woodline Partners LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 28, 2025 | marketbeat.com

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 27, 2025 | finance.yahoo.com

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 27, 2025 | globenewswire.com

Tango Therapeutics starts trial for brain cancer drug

May 23, 2025 | uk.investing.com

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

May 21, 2025 | globenewswire.com

517,426 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Jacobs Levy Equity Management Inc.

May 19, 2025 | marketbeat.com

Q2 EPS Estimate for Tango Therapeutics Increased by Analyst

May 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX, IRON, BHVN, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$13.43 -0.07 (-0.52%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$13.46 +0.04 (+0.26%)

As of 06/13/2025 07:56 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Biohaven NYSE:BHVN

$15.43 -0.16 (-1.05%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$15.44 +0.01 (+0.06%)

As of 06/13/2025 06:55 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Disc Medicine NASDAQ:IRON

$53.71 +1.00 (+1.90%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$55.65 +1.94 (+3.61%)

As of 06/13/2025 05:54 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Tango Therapeutics NASDAQ:TNGX

$4.69 -0.36 (-7.13%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.71 +0.02 (+0.43%)

As of 06/13/2025 07:51 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time